Evidence map›Paper›PMID 28774880›Full record

Trial reportBlood2017

Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.

Elias Jabbour, Nicholas J Short, Guillermo Montalban-Bravo, Xuelin Huang, Carlos Bueso-Ramos, Wei Qiao, Hui Yang, Chong Zhao, Tapan Kadia, Gautam Borthakur and 13 more

Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IIComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04482621 (Decitabine for COVID-19 Pneumonia-ARDS Treatment), which is not on this map. Cited by 86 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 1 pooled it
12.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04482621 phase2suspendednot on this mapstarted 2020, after this paper: background citation

Decitabine for COVID-19 Pneumonia-ARDS Treatment: DART Trial

TypeinterventionalSponsorJohns Hopkins UniversityRan2020 to 2026Enrolled33ConditionsCOVID-19ArmsDecitabine, Placebo Saline
3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 1 synthesis or guideline pooled it, 179 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Therapy of high-risk myelodysplastic syndromes.Bone marrow transplantation · 2026
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 1 country.

Elias JabbourThe University of Texas MD Anderson Cancer Center, Houston, TX.
Nicholas J ShortThe University of Texas MD Anderson Cancer Center, Houston, TX.
Guillermo Montalban-BravoThe University of Texas MD Anderson Cancer Center, Houston, TX.
Xuelin HuangThe University of Texas MD Anderson Cancer Center, Houston, TX.
Carlos Bueso-RamosThe University of Texas MD Anderson Cancer Center, Houston, TX.
Wei QiaoThe University of Texas MD Anderson Cancer Center, Houston, TX.
Hui YangThe University of Texas MD Anderson Cancer Center, Houston, TX.
Chong ZhaoThe University of Texas MD Anderson Cancer Center, Houston, TX.
Tapan KadiaThe University of Texas MD Anderson Cancer Center, Houston, TX.
Gautam BorthakurThe University of Texas MD Anderson Cancer Center, Houston, TX.
Naveen PemmarajuThe University of Texas MD Anderson Cancer Center, Houston, TX.
Koji SasakiThe University of Texas MD Anderson Cancer Center, Houston, TX.
Zeev EstrovThe University of Texas MD Anderson Cancer Center, Houston, TX.
Jorge CortesThe University of Texas MD Anderson Cancer Center, Houston, TX.
Farhad RavandiThe University of Texas MD Anderson Cancer Center, Houston, TX.
Yesid AlvaradoThe University of Texas MD Anderson Cancer Center, Houston, TX.
Rami KomrokjiMoffitt Cancer Center, Tampa, FL.
Mikkael A SekeresCleveland Clinic, Cleveland, OH.
David P SteensmaDana-Farber Cancer Institute, Boston, MA.
Amy DeZernJohns Hopkins University, Baltimore, MD; and.
Gail RobozCornell Medical College, New York, NY.
Hagop KantarjianThe University of Texas MD Anderson Cancer Center, Houston, TX.
Guillermo Garcia-ManeroThe University of Texas MD Anderson Cancer Center, Houston, TX.
The University of Texas MD Anderson Cancer Center · USCleveland Clinic · USCornell University · USDana-Farber Cancer Institute · USJohns Hopkins University · USMoffitt Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Hypomethylating agents (HMAs) improve survival in patients with higher-risk myelodysplastic syndromes (MDS) but are less well-studied in lower-risk disease. We compared the safety and efficacy of low-dose decitabine vs low-dose azacitidine in this group of patients. Adults with low- or intermediate 1-risk MDS or MDS/myeloproliferative neoplasm (MPN), including chronic myelomonocytic leukemia, according to the International Prognostic Scoring System, were randomly assigned using a Bayesian adaptive design to receive either azacitidine 75 mg/m

Indexed as

AdultAgedAged, 80 and overAntimetabolites, AntineoplasticAzacitidineBlood TransfusionCytogenetic AnalysisDecitabineDisease-Free SurvivalHumansLeukemia, Myelomonocytic, ChronicMiddle AgedMyelodysplastic-Myeloproliferative DiseasesMyelodysplastic SyndromesNeoplasmsRiskAntimetabolites, AntineoplasticAzacitidineDecitabine

Identifiers

PMID28774880
PMCPMC5620419
OpenAlexW2742767772

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.